Genprex, Inc. Retained Earnings
Genprex, Inc. (GNPX) had Retained Earnings of -$179.94 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$179.94M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$175.49M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$171.03M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$167.24M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$179.94M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$175.49M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$171.03M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$167.24M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$163.44M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$158.76M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$154.80M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$150.47M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$146.15M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | -$139.66M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$133.69M 10-K · filed 2025-04-01 | |
| 2023-09-30 | -$127.76M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$120.01M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | -$112.03M 10-Q · filed 2023-05-22 | |
| 2022-12-31 | -$102.83M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$96.30M 10-K · filed 2023-03-31 | -$94.99M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$90.16M 10-K · filed 2023-03-31 | -$88.91M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$84.40M 10-K · filed 2023-03-31 | -$83.74M 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$79.09M 10-K · filed 2023-03-31 | -$78.02M 10-K · filed 2022-03-30 |
| 2021-09-30 | -$72.34M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$68.90M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$64.91M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$58.42M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$53.19M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$50.42M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | -$46.05M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$40.48M 10-K · filed 2021-03-26 | |
| 2019-09-30 | -$38.05M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$35.68M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | -$31.98M 10-Q/A · filed 2019-05-20 | |
| 2018-12-31 | -$29.82M 10-K · filed 2020-03-30 | |
| 2018-09-30 | -$26.39M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$24.21M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$18.15M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$17.45M 10-K · filed 2019-04-01 | |
| 2017-09-30 | -$16.79M 10-Q · filed 2017-12-05 | |
| 2016-12-31 | -$14.14M 10-K · filed 2018-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |